Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
Elemento is the director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Sternberg is the clinical director of the Englander Institute for Precision Medicine. Khozin is ...
Stocktwits on MSN
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design
The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.” ・As a result, the FDA no longer considers the study to be “pivotal.” ...
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...
Phase 3b ENCORE data assess inhaled amikacin in MAC lung disease. Read more on efficacy, safety, and patient-reported ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about metabolism, peptides, and the future of self-driven health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results